Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma [Phase 3]
A Phase 3 trial compares DVRd followed by cilta-cetagene autoleucel versus DVRd followed by autologous stem cell transplant in newly diagnos…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating a minimal residual disease–driven strategy using a T-cell redirector after D-VRd therapy in newly diagnose…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A phase 1/2 clinical trial update for an anti-BCMA CAR-T cell therapy in adults with relapsed or refractory multiple myeloma; currently recr…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma [Phase 1]
This Phase 1 clinical trial compares HLX15-SC with DARZALEX FASPRO in combination with lenalidomide and dexamethasone for transplant-ineligi…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT [Phase 1, Phase 2]
Phase 1/2 study evaluating CART-19/BCMA CAR-T cells targeting CD19 and BCMA in high-risk multiple myeloma patients following autologous stem…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS other · 2026-03-17Clinical Trial Update: Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma [NA]
The clinical trial evaluating a CAR-T therapy for relapsed or refractory multiple myeloma was terminated.
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Elimination of Minimal Residual Disease After Transplant [Phase 2]
Phase 2 clinical trial update examining strategies to eliminate minimal residual disease after transplant in multiple myeloma; the study is …
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. [Phase 4]
BLOOD-dose is a Phase 4 platform trial evaluating dose optimization in hematologic diseases, with Waldenström macroglobulinemia and multiple…
-
EMA approval · 2026-03-13EMA Authorised: Carvykti (ciltacabtagene autoleucel) — Janssen-Cilag International NV
EMA has authorised Carvykti (ciltacabtagene autoleucel) for the treatment of multiple myeloma. The product is a CAR-T therapy developed by J…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating a quadruple regimen of isatuximab, carfilzomib, pomalidomide, and dexamethasone for relapsed or refracto…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma [Phase 1]
Phase 1 study evaluating 211At-OKT10-B10 with fludarabine, with or without cyclophosphamide and low-dose total body irradiation, as conditio…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Elranatamab in R/R Multiple Myeloma [Phase 2]
Elranatamab is being studied in a Phase 2 trial for patients with refractory or relapsed multiple myeloma; the study is currently recruiting…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma [Phase 3]
Phase 3 trial evaluating Iberdomide maintenance versus Lenalidomide maintenance after autologous stem cell transplant in newly diagnosed mul…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 study evaluating talquetamab in combination with iberdomide and dexamethasone for relapsed or refractory multiple myeloma is current…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating dabrafenib and/or trametinib in relapsed or refractory multiple myeloma is currently active but not recr…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide [Phase 3]
A Phase 3 trial comparing Talquetamab plus Pomalidomide, Talquetamab plus Teclistamab, and Elotuzumab plus Pomalidomide and Dexamethasone or…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 3]
Sponsored by AbbVie, the Phase 3 trial is evaluating intravenous Etentamig as monotherapy versus standard therapies in adults with relapsed …
-
EMA approval · 2026-03-12EMA Authorised: Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto
EMA authorised Lenalidomide Krka (lenalidomide hydrochloride monohydrate) for several hematologic malignancies, including multiple myeloma, …
-
FDA approval · 2026-03-12FDA Approved: POMALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's supplemental application for pomalidomide, authorizing the generic pomalidomide to be marketed. This represents a su…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) [Phase 3]
A Phase 3 clinical trial (DURGA-4) evaluating AZD0120, a dual-targeted CAR-T therapy against BCMA and CD19, versus standard regimens in rela…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure [EARLY_Phase 1]
Pilot Phase 1 study evaluating daratumumab with CyBorD (cyclophosphamide, bortezomib, dexamethasone) in newly diagnosed multiple myeloma pat…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: ELISA in Relapsed/Refractory MM [Phase 2]
This clinical trial update describes a Phase 2 study of ELISA in relapsed/refractory multiple myeloma, which is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating Cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma; currently recruiti…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: CAR- PRISM (PRecision Intervention Smoldering Myeloma) [Phase 2]
Phase 2 trial update for CAR-PRISM, a cellular therapy for multiple myeloma and smoldering multiple myeloma, sponsored by Dana-Farber Cancer…
-
CLINICAL_TRIALS research · 2026-03-12Clinical Trial Update: Long-Term Follow-up Study
Long-term follow-up study of relapsed/refractory non-Hodgkin lymphoma is currently enrolling by invitation, sponsored by Caribou Biosciences…